Agenda
Applications for consideration at this meeting
- 1165.1 Pre-implantation genetic diagnosis (PGD) assessment
- 1216.1 Cystic fibrosis transmembrane regulator (CFTR) testing
- 1308 Local anaesthetic (LA) nerve blockade for post-surgical analgesia
- 1331 Review of archival tissue for further diagnostic testing
- 1360.1 Specialist dermatology services delivered by asynchronous store and forward technology (resubmission)
- 1392 Corneal Collagen Cross Linking as early intervention in progressive keratoconus
- 1397 mpMRI prostate diagnostic scans
- 1422 Minimally invasive, lumbar decompression and dynamic stabilisation using an interlaminar device, with no rigid fixation to the vertebral pedicles, implantation between the spinous processes of one or two lumbar motion segments
- 1424 MR guided biopsy procedures for diagnosis of prostate cancer
- 1429 Intraoperative Radiotherapy for Early Stage Breast Cancer
- 1432 Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies
- 1440 PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer
- 1443 Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke
- 1456 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia
- 1479 1479r - Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369
Related information
Committee: